Case report: Overlap syndrome of neuromyelitis optica spectrum disorder with anti-Argonaute antibodies

Front Immunol. 2024 Jun 3:15:1366531. doi: 10.3389/fimmu.2024.1366531. eCollection 2024.

Abstract

Aquaporin-4 antibodies (AQP4-Abs) are a diagnostic marker for patients with a demyelinating disease called neuromyelitis optica spectrum disorder (NMOSD). Anti-Argonaute antibodies (AGO-Abs) present as potential biomarkers of the overlap syndrome between NMOSD and other autoimmune diseases. In this paper, we present the case of an adult woman with numbness, tingling, and burning sensations in her arms and subsequent bilateral internuclear ophthalmoplegia. Brain-cervical-thoracic magnetic resonance imaging (MRI) showed T2 hyperintensities in the dorsal brainstem and around the midbrain aqueduct and longitudinally transverse myelitis with homogeneous enhancement on gadolinium-enhanced MRI. The contemporaneous detection of AQP4- and AGO-Abs led to a definite diagnosis of overlap syndrome of NMOSD with AGO-Abs. The patient was treated with immunosuppressive agents, including corticosteroids and immunoglobulins, and achieved remission. This case highlights a novel phenotype of NMOSD with AGO-Abs overlap syndrome, which presents with relapsing brainstem syndrome and longitudinally extensive myelitis with acute severe neurological involvement. The promising prognosis of the disease could serve as a distinct clinical profile. Broad screening for antibodies against central nervous system autoimmune antigens is recommended in suspected patients with limited or atypical clinical manifestations.

Keywords: Brainstem encephalitis; aquaporin-4 antibody; argonaute antibody; longitudinally extensive myelitis; neuromyelitis optica spectrum disorder.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aquaporin 4 / immunology
  • Autoantibodies* / blood
  • Autoantibodies* / immunology
  • Biomarkers
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Magnetic Resonance Imaging
  • Middle Aged
  • Neuromyelitis Optica* / diagnostic imaging
  • Neuromyelitis Optica* / drug therapy
  • Neuromyelitis Optica* / immunology

Substances

  • AQP4 protein, human
  • Aquaporin 4
  • Autoantibodies
  • Biomarkers
  • Immunosuppressive Agents

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Science and Technology Program of Shaanxi Province (2022SF-381, 2023-YBSF-048, 2022SF-507, 2023-YBSF-052), the Project of Shaanxi Administration of Traditional Chinese Medicine (2022-SLRH-LJ-013), the Science and Technology Program of Xi’an city (22YXYJ0061, 22YXYJ0074), the Project of Science and Technology Association of Xi’an Young Talent Lifting Program (095929221312).